Latest radiation treatment Stories
Hypofractionated radiation treatment, a newer type of radiation treatment that delivers higher doses of radiation in fewer treatments than conventional radiation therapy, is significantly more effective in stopping cancer from growing in high risk patients.
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone.
Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone, however there is no significant benefit for low-risk patients.
After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area.
High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent).
The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.
Most Recent Indication Expands Treatment Platform to Allow Axxent(R) System to Deliver Surface Brachytherapy, Including Intraoperative Radiation Therapy (IORT) SUNNYVALE, Calif., March 4 /PRNewswire/ -- Xoft, Inc., today announced that it has received clearance from the U.S.